IL22RA1 and ulcerative colitis: As ABD-derived blockers can be effectively produced in genetically engineered L. lactis probiotic strains, it offers a promising avenue for orally administrated IL-22R1-targeted therapy for gut inflammatory conditions such as ulcerative colitis.